Safety assessment of biopharmaceuticals

• Published in: Journal of toxicological sciences Vol. 33; no. 3; p. 277
• Main Authors: Nakazawa, Takahiro, Kurokawa, Misao, Kimura, Kazuya, Wakata, Akihiro, Hisada, Shigeru, Inoue, Tadashi, Sagami, Fumio, M. Heidel, Shawn, Kawakami, Koji, Shinoda, Kazutoshi, Onodera, Hiroshi, Kumagai, Yuji, Ohno, Yasuo, Kawamura, Nobuyuki, Yamazaki, Tsuneyoshi, Inoue, Tohru
• Format: Journal Article
• Language: English
• Published: Suita Japan Science and Technology Agency 30-05-2008
• ISSN: 0388-1350; 1880-3989

Safety assessment of biopharmaceuticals in preclinical studies is guided by the ICH S6 guideline issued in 1997. Along with enormous experiences and knowledge on safety assessment of some classes of biopharmaceuticals over the last decade, the necessity and feasibility of updating the guideline has been discussed. According to a recommendation by safety experts at the ICH meeting in Chicago in 2006, regional discussions of ICH S6 were held in the USA, EU and Japan. The meeting to clarify the values, challenges and recommendations for ICH S6 from Japanese perspective was held as a part of the first Drug Evaluation Forum in Tokyo on August 10, 2007. Of utmost importance, the "case-by-case" approach must be preserved as the basic principle of the ICH S6 guideline. It is our opinion that oligonucleotides, siRNA, aptamers and related molecules should be excluded from ICH S6 and may be more appropriate for separate guidance. However, based on experiences and accumulated knowledge, there are a number of issues that can be updated including new types of biopharmaceuticals such as bioconjugates, use of homologous proteins and transgenic animals, reproductive/developmental toxicity studies in non-human primates, in vitro cardiac ion channel assay and alternative approaches for carcinogenicity assessment. Preliminary recommendations for some of these topics were outlined at the meeting. The overall Japanese recommendation is that the ICH S6 guideline should be updated to address these topics.